July 15, 2025Journal of the National Comprehensive Cancer Network
Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia Therapy
Authors
Discussion
Loading...
Member takes
Implication
Review demonstrates improved outcomes in B-cell acute lymphoblastic leukemia using immunotherapy agents, suggesting enhanced survival compared to chemotherapy.
Key Points
- Blinatumomab and inotuzumab ozogamicin improve outcomes in patients with B-cell acute lymphoblastic leukemia (B-ALL).
- These agents lead to high rates of deep measurable residual disease negativity compared to chemotherapy alone.
- The review discusses potential chemotherapy-free approaches and the role of CAR T-cell therapies for high-risk B-ALL patients.
- Incorporating immunotherapy may reduce the need for intensive chemotherapy and allogeneic stem cell transplantation.
Cite This Study
Haddad et al. (2025) studied this question.